South Korea
· Delayed Price · Currency is KRW Korea Arlico Pharm Co.,Ltd. Statistics
Total Valuation
Korea Arlico Pharm Co.,Ltd. has a market cap or net worth of KRW 61.84 billion. The enterprise value is 91.58 billion.
| Market Cap | 61.84B |
| Enterprise Value | 91.58B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Korea Arlico Pharm Co.,Ltd. has 15.33 million shares outstanding. The number of shares has increased by 0.01% in one year.
| Shares Outstanding | 15.33M |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 40.04% |
| Owned by Institutions (%) | 0.10% |
| Float | 9.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.34 |
| PB Ratio | 0.74 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.33 |
| EV / Sales | 0.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.57 |
Financial Position
The company has a current ratio of 1.10, with a Debt / Equity ratio of 57.45.
| Current Ratio | 1.10 |
| Quick Ratio | 0.61 |
| Debt / Equity | 57.45 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.36 |
| Interest Coverage | -6.97 |
Financial Efficiency
Return on equity (ROE) is -10.05% and return on invested capital (ROIC) is -5.31%.
| Return on Equity (ROE) | -10.05% |
| Return on Assets (ROA) | -4.18% |
| Return on Capital (ROIC) | -5.31% |
| Revenue Per Employee | 1.60B |
| Profits Per Employee | -79.15M |
| Employee Count | 112 |
| Asset Turnover | 1.08 |
| Inventory Turnover | 2.81 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.51% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -36.51% |
| 50-Day Moving Average | 4,673.50 |
| 200-Day Moving Average | 5,167.80 |
| Relative Strength Index (RSI) | 39.97 |
| Average Volume (20 Days) | 149,378 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Korea Arlico Pharm Co.,Ltd. had revenue of KRW 178.83 billion and -8.86 billion in losses. Loss per share was -677.32.
| Revenue | 178.83B |
| Gross Profit | 96.88B |
| Operating Income | -11.06B |
| Pretax Income | -10.33B |
| Net Income | -8.86B |
| EBITDA | -5.04B |
| EBIT | -11.06B |
| Loss Per Share | -677.32 |
Balance Sheet
The company has 17.68 billion in cash and 47.42 billion in debt, giving a net cash position of -29.74 billion or -1,940.29 per share.
| Cash & Cash Equivalents | 17.68B |
| Total Debt | 47.42B |
| Net Cash | -29.74B |
| Net Cash Per Share | -1,940.29 |
| Equity (Book Value) | 82.53B |
| Book Value Per Share | 5,482.97 |
| Working Capital | 6.95B |
Cash Flow
In the last 12 months, operating cash flow was -7.29 billion and capital expenditures -12.77 billion, giving a free cash flow of -20.06 billion.
| Operating Cash Flow | -7.29B |
| Capital Expenditures | -12.77B |
| Free Cash Flow | -20.06B |
| FCF Per Share | -1,308.76 |
Margins
Gross margin is 54.18%, with operating and profit margins of -6.19% and -4.96%.
| Gross Margin | 54.18% |
| Operating Margin | -6.19% |
| Pretax Margin | -5.78% |
| Profit Margin | -4.96% |
| EBITDA Margin | -2.82% |
| EBIT Margin | -6.19% |
| FCF Margin | -11.22% |
Dividends & Yields
Korea Arlico Pharm Co.,Ltd. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.01% |
| Shareholder Yield | -0.01% |
| Earnings Yield | -16.79% |
| FCF Yield | -32.44% |
Stock Splits
The last stock split was on June 15, 2021. It was a forward split with a ratio of 1.5.
| Last Split Date | Jun 15, 2021 |
| Split Type | Forward |
| Split Ratio | 1.5 |